# Validation of a machine-learning-based algorithm to predict preeclampsia-related adverse outcomes on a real-world dataset

**Authors:** Ameli Hoyler, Oliver Rieger, Max Hackelöer, Mark Neznansky, Wolfgang Henrich, Lisa Lorenz-Meyer, Stefan Verlohren

PMC · DOI: 10.1007/s00404-025-08261-7 · Archives of Gynecology and Obstetrics · 2026-02-06

## TL;DR

A simplified machine learning model accurately predicts preeclampsia-related outcomes using fewer features, potentially aiding clinical decisions to improve maternal and neonatal health.

## Contribution

The study introduces a streamlined machine learning model with reduced features that maintains high accuracy for predicting preeclampsia outcomes.

## Key findings

- Reduced-feature models showed comparable accuracy to original models across all endpoints.
- The model achieved an AUROC of 0.92 in training and 0.89 in validation for predicting adverse outcomes.
- The model's performance for predicting delivery timing remained strong with AUROCs above 0.80.

## Abstract

Preeclampsia is a major obstetric disorder. Machine learning (ML) models incorporating angiogenic biomarkers show promise in predicting related adverse outcomes, but refinement is needed for clinical use. This study aimed to reduce features to a clinically meaningful set and to develop and validate predictive endpoints for preeclampsia-associated outcomes.

A model with a reduced feature set was derived from a training cohort of 1,634 patients (2,

412 visits) and then tested on a validation cohort of 402 patients (540 visits). Three machine learning models were developed to predict (1) adverse outcomes overall, (2) delivery within 14 days before 34 weeks of gestation, and (3) delivery within 7 days after 34 weeks, using 13 features versus 114 originally.

Reduced-feature models demonstrated comparable accuracy to original models across all endpoints. Model 1 (any adverse outcome) achieved an Area Under the Receiver Operating Characteristic Curve (AUROC) of 0.92 (95% CI: 0.88–0.96) in training and 0.89 (95% CI: 0.84–0.93, p = 0.31) in the validation cohort, respectively. For delivery within 14 days, the AUROC was 0.92 (95% CI: 0.87–0.96) in training and 0.85 (95% CI: 0.78–0.92) in validation (p = 0.13). Delivery within 7 days showed AUROCs of 0.79 (95% CI: 0.70–0.87) and 0.80 (95% CI: 0.75–0.85) (p = 0.78).

A machine learning model with a significantly reduced number of features can accurately predict clinically relevant preeclampsia outcomes. The identified endpoints (timing of delivery and adverse events) could support clinical decision-making and help reduce maternal and neonatal morbidity and mortality.

## Linked entities

- **Diseases:** preeclampsia (MONDO:0005081)

## Full-text entities

- **Genes:** PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}
- **Diseases:** edema (MESH:D004487), abdominal pain (MESH:D015746), deaths (MESH:D003643), fetal abnormalities (MESH:D005315), headache (MESH:D006261), HELLP (MESH:D017359), preterm preeclampsia (MESH:D047928), hypertensive pregnancy disorders (MESH:D046110), GA (MESH:D016640), obstetric disorder (MESH:D048949), weight gain (MESH:D015430), fetal anomalies (MESH:D000013), Low Platelets-Syndrome (MESH:D009800), RDS (MESH:D012128), prematurity (MESH:C536271), pregnancy disorder (MESH:D011254), eclampsia (MESH:D004461), hypertension (MESH:D006973), Preeclampsia (MESH:D011225), oligohydramnios (MESH:D016104), renal failure (MESH:D051437), IVH (MESH:D000074042), maternal death (MESH:D063130), AO (MESH:D011248), chromosomal disorders (MESH:D025063), pulmonary edema (MESH:D011654), visual disturbances (MESH:D014786), cerebral hemorrhage (MESH:D002543), NEC (MESH:D020345), fetal growth restriction (MESH:D005317), DIC (MESH:D004211), Hemolysis (MESH:D006461), proteinuria (MESH:D011507), fetal death (MESH:D005313)
- **Chemicals:** magnesium (MESH:D008274), creatinine (MESH:D003404)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12881101/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12881101/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12881101/full.md

---
Source: https://tomesphere.com/paper/PMC12881101